A study which was funded by Cell Pathways Inc., developer of the drug Exisulind, suggest that Exisulind may delay disease progression in men with recurrent prostate cancer according to Dr. Erik Goluboff, Assistant Professor of Urology at Columbia University College of Physicians & Surgeons, Director of Urology at The Allen Pavilion of New York-Presbyterian Hospital, [...]
High Intensity Focused Ultrasound (HIFU) is a minimally invasive procedure that uses ultrasound energy to destroy cancerous tissue with focused sound waves. It has been used for a period of time in both Europe and Mexico as a primary prostate cancer treatment. Currently, in the United States there is a phase III trial being conducted [...]
Investigators have reported, at the American Society for Therapeutic Radiation and Oncology (ASTRO) 50th Annual Meeting, that when radiation is added to anti-androgen therapy (ADT), survival rates are increased by 50% in men receiving only ADT. "This randomized trial is the first to show that men with locally advanced prostate cancer will survive substantially longer [...]
It is common knowledge that androgens play a role in the production of red blood cells. The lack of androgens cause the hematocrit (proportion of blood volume that is occupied by red blood cells) level to fall in most men with prostate cancer who are on a hormone blockade. About 10% of men on a [...]
Remember when we were younger, I mean 5, 6 and 7 years old. Life was full of hope and dreams. We wanted to be firemen, policemen and astronauts. The future glowed full of our visions of greatness and desires. Nothing could possibly hold us back. Our imaginations ran free, we had no barriers. Now is [...]